Menu
Recruiting NCT07289399

Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS?

No phase Interventional Psoriasis Polycystic Ovary Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: exercise and diet restriction, diet restriction.
Who it may be relevant to
Registry conditions: Psoriasis, Polycystic Ovary Syndrome. Basic parameters: 35 years — 45 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Women with psoriasis usually develop many complications including polysyctic ovarian syndrome (PCOS). Nowdays, diet restriction combimed with phsyical exercises may improve both problems

Detailed description

Forty Women with psoriasis with PCOS will be enrolled to be catogrized to Group I or group II. Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week. Also Group I will follow low calorie diet and daily metformin for 12 weeks. Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks

Interventions

  • Behavioral exercise and diet restriction
    Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week for 12 weeks. Also Group I will follow low calorie diet and daily metformin for 12 weeks.
  • Behavioral diet restriction
    Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks

Primary outcome measures

  • Psoariasis area and severity index [Time frame: it will be measured after 12 weeks]
Secondary outcome measures (12)
  • body mass index [Time frame: It will be measured after 12 weeks]
  • waist circumference [Time frame: It will be measured after 12 weeks]
  • waist hip ratio [Time frame: It will be measured after 12 weeks]
  • testesterone [Time frame: it will be measured after 12 weeks]
  • ratio of luteinizing hormone and follicle-stimulating hormone [Time frame: It will be measured after 12 weeks]
  • Dehydroepiandrosterone [Time frame: It will be measured after 12 weeks]
  • Dermatology life Quality Index [Time frame: It will be measured after 12 weeks]
  • insuiln [Time frame: It will be measured after 12 weeks]
  • fasting blood glucose [Time frame: It will be measured after 12 weeks]
  • HOMA-IR [Time frame: It will be measured after 12 weeks]
  • triglycerides [Time frame: It will be measured after 12 weeks]
  • total cholesterol [Time frame: It will be measured after 12 weeks]

Eligibility criteria

Inclusion criteria

  • obese (class I) women
  • chronic plaque psoriasis
  • polyscytic ovarian syndrome

Exclusion criteria

  • cardiac dysfucntions
  • liver diseases
  • repsiratory disease
  • vascular diseases

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Cairo University — Giza

Identifiers

NCT: NCT07289399 · IRB00014233-58

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗